Literature DB >> 15942250

Clinical epidemiology of cardiovascular disease in chronic kidney disease.

K Kundhal1, C E Lok.   

Abstract

Cardiovascular disease (CVD) is the most common cause of death in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The clinical epidemiology of CVD in CKD is challenging due to a prior lack of standardized definitions of CKD, inconsistent measures of renal function, and possible alternative effects of 'traditional' CVD risk factors in patients with CKD. These challenges add to the complexity of the role of renal impairment as the cause or the consequence of cardiovascular disease. The goal of this review is to summarize the current evidence on: (1) the incidence and prevalence of CVD in chronic renal insufficiency and in ESRD, (2) risk factors for CVD in CKD, (3) the outcomes of patients with renal failure with CVD, and (4) CKD as a risk factor for CVD. The epidemiological associations implicating the huge burden of CVD throughout all stages of CKD highlight the need to better understand and implement adequate screening, and diagnostic and treatment strategies. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 15942250     DOI: 10.1159/000086221

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  20 in total

1.  Cardiorenal syndromes.

Authors:  Peter A McCullough; Aftab Ahmad
Journal:  World J Cardiol       Date:  2011-01-26

Review 2.  Cardiac metabolic remodelling in chronic kidney disease.

Authors:  Nikayla Patel; Muhammad Magdi Yaqoob; Dunja Aksentijevic
Journal:  Nat Rev Nephrol       Date:  2022-05-30       Impact factor: 42.439

3.  Exploring metabolic dysfunction in chronic kidney disease.

Authors:  Adrian D Slee
Journal:  Nutr Metab (Lond)       Date:  2012-04-26       Impact factor: 4.169

4.  Renal function is related to severity of coronary artery calcification in elderly persons: the Rotterdam study.

Authors:  Abdelilah El Barzouhi; Suzette Elias-Smale; Abbas Dehghan; Rozemarijn Vliegenthart-Proença; Matthijs Oudkerk; Albert Hofman; Jacqueline C M Witteman
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

5.  Cardiorenal syndromes: pathophysiology to prevention.

Authors:  Peter A McCullough
Journal:  Int J Nephrol       Date:  2010-12-01

6.  Metabolic syndrome and renal injury.

Authors:  Yi-Jing Sheen; Wayne Huey-Herng Sheu
Journal:  Cardiol Res Pract       Date:  2011-03-13       Impact factor: 1.866

7.  Effects of lowering dialysate calcium concentrations on arterial stiffness in patients undergoing hemodialysis.

Authors:  Jwa-Kyung Kim; Sung Jin Moon; Hyeong Cheon Park; Jae Sung Lee; Soung Rok Sim; Sung Chang Bae; Sung Kyu Ha
Journal:  Korean J Intern Med       Date:  2011-09-13       Impact factor: 2.884

8.  Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation.

Authors:  Kathryn K Stevens; Emily P McQuarrie; William Sands; Dianne Z Hillyard; Rajan K Patel; Patrick B Mark; Alan G Jardine
Journal:  Int J Nephrol       Date:  2011-08-09

9.  Prevalence and predictors of aortic dilation as a novel cardiovascular complication in children with end-stage renal disease.

Authors:  Ahmad Kaddourah; Susan Uthup; Peace Madueme; Matthew O'Rourke; David K Hooper; Michael D Taylor; Steven D Colan; John L Jefferies; Marepalli B Rao; Jens Goebel
Journal:  Clin Nephrol       Date:  2015-05       Impact factor: 0.975

10.  Escalating antihypertensive medications in end-stage renal disease patients does not improve blood pressure control.

Authors:  Mihály Tapolyai; Jariatul Karim; Atif Fakhruddin
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-03       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.